Logo

Grifols Acquires Remaining 56% of GigaGen for ~$80M

Share this

M&A

Grifols Acquires Remaining 56% of GigaGen for ~$80M

Shots:

  • Grifols acquires the remaining 56% share of GigaGen for $80M. The acquisition will add GigaGen’s pipeline of recombinant polyclonal Abs- including GIGA-2050 and boost Grifol’s portfolio if I-O therapies
  • Earlier- in 2017- Grifols acquired a 44% stake in GigaGen- when the two companies collaborated to develop polyclonal antibodies under a $50M pact
  • GIGA-2050 is expected to be evaluated in P- I trial in the US in spring 2021- following the IND approval

 ­ Ref: PRNewswire | Image: Yicai Global

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions